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Abstract
Background: Leucine-rich repeat C4 protein (LRRC4) is a new member of the leucine-rich repeat
(LRR) superfamily. It is not only a brain-specific gene but also a novel candidate for tumor
suppression. LRRC4 inactivation is commonly found in glioma cell lines and primary glioma biopsies.
However, little is known about the mechanism controlling LRRC4 expression. In a previous study,
we did not find any genetic alteration in LRRC4 in primary glioma, which led us to explore an
alternative mechanism underlying this phenomenon.
Methods: In the present paper, we cloned the LRRC4 promoter with characteristics of a CpG
island by luciferase reporter assay. Then, the CpG methylation status around the LRRC4 promoter
region in glioma cell lines and primary gliomas was examined by methylation-specific PCR and
bisulfite DNA sequencing. In order to demonstrate a functional association between LRRC4
promoter methylation and its gene inactivation, we performed DNA demethylation analysis with
two human glioma cell lines using methylation-specific PCR and RT-PCR.
Results: The sequence spanning positions -835 to -293 relative to the translation start site was
identified as the LRRC4 promoter; this sequence is a TATA- and CAAT- less, high GC content
region. It was found that LRRC4 promoter activity is strongly suppressed after treatment with SssI
methylase in vitro. Furthermore, LRRC4 promoter methylation was observed by methylation-
specific PCR in two glioma cell lines and all 30 primary glioma specimens, but not in normal brain
tissue. Bisulfite DNA sequencing showed that most of the CpG sites were located around the
LRRC4 promoter methylated in glioma cells and tissues, but not in normal brain tissue. In addition,
the methylase inhibitor 5-Aza-2'-deoxycytidine could induce LRRC4 mRNA expression and LRRC4
promoter partial demethylation in SF126 and SF767 glioma cells.
Conclusion: Methylation-mediated inactivation of LRRC4 is a frequent and glioma-specific event,
and it may be a potential biomarker for diagnosis or prognosis, or serve as a therapeutic target.
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Background
Gliomas are the most common malignant tumors in the
adult central nervous system and account for 50 to 60% of
primary brain tumors. These cancers exhibit a relentless
malignant progression characterized by widespread inva-
sion throughout the brain, and thus usually result in a
poor prognosis [1]. Although multiple genetic alterations
are involved in the development and progression of
malignant gliomas [2,3], epigenetic silencing of wild-type
tumor suppressor genes via aberrant promoter hyper-
methylation has also been shown to occur [4-6]. Aberrant
promoter methylation of CpG island-associated genes is a
common epigenetic alteration associated with the inacti-
vation of tumor suppressor and other genes in human
cancers [7-9]. Unmethylated in normal tissues, promoters
of these genes can become methylated de novo in cancer
cells. This change is accompanied by alterations in histone
modification and chromatin conformation, rendering the
promoter transcriptionally inert [10].
Such epigenetic mechanisms have been implicated in the
inactivation of several key regulators of the cell cycle (RB,
p16INK4A, p73), DNA repair (O6MGMT), apoptosis (DAP
kinase), angiogenesis (THBS1), and invasion (TIMP3) in
glioma [11]. Recently, novel hypermethylated genes in
glioma have been identified using a candidate gene
approach or by a genome-wide screening method. The
former revealed that genes such as EMP3, TMS1/ASC,
SLC5A8, hMLH and PTEN are frequently targeted for DNA
methylation-mediated silencing in glioma [4,5,12,13]. A
genome-wide screen using a combined approach of phar-
macologic inhibition of epigenetic modifications and
gene expression microarrays also revealed that several
novel genes are subject to aberrant hypermethylation in
glioma [14,15]. Thus, aberrant methylation events have
become critical to our understanding of the initiation and
progression of human brain malignancies and may serve
as a biomarker for diagnosis, prognosis and susceptibility
to treatment.
Leucine-rich repeat C4 protein (LRRC4) is a new member
of the leucine-rich repeat (LRR) superfamily located at
7q31-32 [16]. It was found to be predominantly expressed
in normal brain tissue and involved in early nervous sys-
tem development and differentiation [17], but the expres-
sion of LRRC4 was absent in several malignant glioma cell
lines [18]. Similarly, it was absent or significantly down-
regulated in 87.5% of primary glioma biopsies [16]. More
importantly, LRRC4 had the potential to suppress tumor-
igenesis of U251 malignant glioma cells in vivo and cell
proliferation in vitro [19]. Recent studies show that
LRRC4 can block U251 cells in G0/G1 and induce U251
cell-growth arrest and differentiation by down-regulating
the ERK/Akt/NF-κB, STAT3 and JNK2/p-c-Jun/p53 signal-
ing pathways [18]. Therefore, the loss of LRRC4 function
may be an important event in the progression of gliomas
and may act as a novel candidate for tumor suppression.
However, little is known about the mechanism of LRRC4
expression loss or down- regulation in glioma cell lines
and biopsies. No known studies have found genetic alter-
ations in the LRRC4 coding sequence in glioma biopsies
or cell lines [18]. This lack of findings led us to explore an
alternative mechanism underlying inactivation of LRRC4
in glioma.
In the present study, we cloned the LRRC4 promoter with
characteristics of a CpG island. Then, CpG methylation
status around the LRRC4 promoter region in glioma cell
lines and primary gliomas was examined by methylation-
specific PCR and bisulfite DNA sequencing. In order to
demonstrate a functional association between LRRC4 pro-
moter methylation and its gene inactivation, we per-
formed DNA demethylation analysis with two human
glioma cell lines using methylation-specific PCR and RT-
PCR.
Methods
Cell lines and tumor samples
Thirty fresh tumor samples were collected after informed
consent was obtained from patients who underwent brain
operations for glioma at Xiangya Hospital (Hunan, Peo-
ple's Republic of China). The samples were snap-frozen
immediately following resection and stored in liquid
nitrogen until processing. The 17 male and 13 female
patients were aged from 17 to 68 years (mean age at regis-
tration = 42 years). Tumors were graded and classified
according to the World Health Organization (2007),
including astrocytoma (grade I (1), grade II-III (17)), oli-
godendroglioma (grade II (5)), oligoastrocytoma (grade II
(3)), and glioblastoma (grade IV (4)) [33]. For compari-
son, normal human tissues from patients without cancer
were obtained at the time of autopsy.
Human glioblastoma-derived cell lines SF126 and SF767
were obtained from the Cell Research Institute of Peking
Union Medical College (Peking, China) and cultured in
minimal essential medium (MEM). Cos7 and Hela were
obtained from American Type Culture Collection and
maintained in Dulbecco's modified Eagle's medium
(DMEM). All cells were supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/mL penicillin
and 100 ug/mL streptomycin and cultured at 37C with
5% CO2.
Cloning and analysis of the LRRC4 5' upstream regulatory 
region
The LRRC4 promoter region in the 5' end of humans was
predicted using the PromoterInspector and PromoterScan
programs. The CpG island was found using CpGplot from
the European Molecular Biology Open Software Suite. ToBMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
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obtain the 5' flanking region of the LRRC4  gene, PCR
amplification was performed on human genomic DNA
(forward primer 5'-ATTGGTACCGGCGAGCTCACAG-
GGCAGGG-3', reverse primer 5'-CTTAGATCTCTGGA-
GAAGGAGGTGGGGAG-3'). After an initial denaturation
step (94°C for 5 min), the PCR reactions were carried out
for 32 cycles at 94°C for 30 sec, 62°C for 30 sec, and 72°C
for 2 min, with a final extension of 10 min at 72°C. The
PCR product was purified using a gel Purification Kit and
cloned into the T/A cloning vector pGEMT-Easy
(Promega). Positive clones of pT/A-2475/-101 were iso-
lated and sequenced.
Luciferase-reporter plasmid constructs and assay
The 5' upsteam regulatory region of the LRRC4 gene was
subcloned into the KpnI and Bgl II restriction sites of the
pGL3-enhancer vector (Promega). Construct naming is
based on the position of the promoter fragments (pGL3-
2475/-101). Four deletion constructs of the LRRC4 pro-
moter region were created (pGL3-1483/-101, pGL3-835/-
101, pGL3-293/-101 and pGL3-835/-293), originating
from the construct pGL3 -2475/-101 by PCR amplifica-
tion using the primers listed in Table 1. Sense primers for
generating the reporter constructs described above con-
tained an adaptor with a KpnI restriction site (GGTACC)
at the 5' end. Anti-sense primers contained an adaptor
with a Bgl II restriction site (AGATCT). The promoter frag-
ments were then subcloned into the KpnI/Bgl II sites of
the pGL3 enhancer vector and sequenced.
Transfection was performed with Lipofectamine™ Reagent
(Invitrogen, Carlsbad, CA). 5×105 cells were seeded in
each well of 24-well tissue plates. When cells reached 50–
80% confluence, they were cotransfected using 1 μg of
each DNA construct in pGL3-enhancer and 0.25 μg
SV40β-galactosidase vector for normalizing transfection
efficiency per well according to manufacturer's instruc-
tions. Firefly luciferase activity was measured in cell
lysates 48 h after transfection by using the Luciferase Assay
System (Promega) and a luminometer. β-galactosidase
activity was measured in cell lysates by the β-galactosidase
Enzyme Assay System (Promega). Experiments were
repeated at least three times with three replicates per sam-
ple for each experiment. Results are normalized against β-
galactosidase activity.
Methylation of report plasmid constructs in vitro
pGL3-835/-293 report plasmid constructs were methyl-
ated in vitro by SssI methylase (New England Biolabs)
treatment following the manufacturer's instructions. Cells
were transfected by methylated or mock-methylated con-
structs as described above.
DNA extraction and Bisulfite modification
Genomic DNA from cells and tissues was prepared using
a DNA Extraction Kit (TaKaRa) according to manufac-
turer's instructions. Five hundred nanograms of genomic
DNA was modified and purified using an EZ DNA Meth-
ylation-Gold Kit (ZYMO RESEARCH), following the man-
ufacturer's protocol. Modified DNA was used
immediately or stored at -80°C for up to six months.
Methylation-Specific PCR
The methylation-specific PCR primers were designed
according to the promoter-active DNA sequence using
Methyl Primer Express v1.0. Modified DNA was amplified
by two different primer pairs specific to the unmethylated
(U) and methylated (M) LRRC4  promoter sequences,
respectively. For the methylated (M) sequence, the for-
ward and backward primers were 5'-AGCGTAGTATT-
TAGCGAGTGC-3' and 5'-TAAACCCTAACACCGACTCG-
3'.
For the unmethylated (U) sequence, the primers were for-
ward 5'-GGGAGTGTAGTATTTAGTGAGTGT-3' and back-
ward 5'-TAAACCCTAACACCAACTCACTC-3'. PCR
amplification was performed for a total of 35 cycles with
an annealing temperature of 58°C. Methylation specific
PCR products were analyzed by a 2% agarose gel and
stained with ethidium bromide.
Bisulfite Sequencing
In order to cover the whole promoter region of LRRC4,
two PCR regions were amplified using primers that
Table 1: Primer Pairs Used for Generating LRRC4 Promoter Constructs pGL3-2475/-101, pGL3-1483/-101, pGL3-835/-101, pGL3-293/-
101 and pGL3-835/-293
pGL3-2475/-101 Forward: 5'-ATTGGTACCGGCGAGCTCACAGGGCAGGG-3'
Reverse: 5'-CTTAGATCTCTGGAGAAGGAGGTGGGGAG-3'
pGL3-1483/-101 Forward: 5'-ATCGGTACCAGTATGCGTCAGCAGTACATTCACG-3'
Reverse: 5'-CTTAGATCTCTGGAGAAGGAGGTGGGGAG-3'
pGL3-835/-101 Forward:5'-ATCGGTACCAACACCTCCTCTTAACTCTCGCC-3'
Reverse: 5'-CTTAGATCTCTGGAGAAGGAGGTGGGGAG-3'
pGL3-293/-101 Forward:5'-ATTGGTACCTGCTTTCCTGCCTTCCTTCC-3'
Reverse: 5'-CTTAGATCTCTGGAGAAGGAGGTGGGGAG-3'
pGL3-835/-293 Forward:5'-ATCGGTACCAACACCTCCTCTTAACTCTCGCC-3'
Reverse: 5'-ATTAGATCTGCACTGGCGTGGTGTCCTTA-3'BMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
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avoided CpG sites. For Region 1, primers were 5'-GYG-
GATTGGAGAATTGATTT TT-3' and 5'-AACTATACAAATA-
CATACCCCCCCC-3'. For Region 2, primers were 5'-
GAGGGGGGGGTATGTATTTGTATAGT-3' and 5'-
CCCACCCTCAAAACAAACCC TC-3'. The PCR amplifica-
tion was performed for a total of 38 cycles with annealing
temperature of 56°C. PCR products were gel-purified and
cloned into the T/A cloning vector pGEMT-Easy
(Promega). Ten subclones were isolated and identified by
double digestion and sequencing.
5'-Aza-dC treatment of cell lines
The human glioblastoma-derived cell lines SF126 and
SF767 were grown for 4 days in the presence of various
concentrations of 5-Aza-dC (2.5, 5, 10 and 15 μM). Fresh
drug was added every 24 h. RNA and DNA were separately
isolated.
RT-PCR
RNA was isolated from harvested cells with Trizol (Invit-
rogen) reagent and then treated with DNase (Roche) to
eliminate contaminated DNA. Reverse transcription of the
RNA was performed according to the instructions of
Promega. To amplify LRRC4, 2 μl of cDNA was used for
each PCR using the primers, 5'-CAACTTGGCCCACAAT
AACC-3' (forward) and 5'-CATCCGACCCTCAGAAATGT-
3' (reverse). The primers for GAPDH were 5'-GTCAGT-
GGTGGACCTGACC T-3' (forward) and 5'-AGGGGAGAT-
TCAGTGTGGTG-3'(reverse). The GAPDH primers were
added to the PCR at the end of the tenth cycle as control
experiments. Ten microliters of each reaction was then
run on 2% agarose gel and stained with ethidium bro-
mide.
Results
Cloning and analysis of the 5' upstream regulatory region
To clone the LRRC4  promoter region, a database was
searched against the human genomic DNA using LRRC4
(Genbank accession No. AF196976) as the query http://
www.ncbi.nlm.nih.gov/BLAST to reveal the 5'upstream
sequence of the LRRC4 gene. Several bioinformatics tools
were used to identify the potential promoter region of the
LRRC4 gene. A 605-bp region spanning positions -814 to
-210 was identified as the potential promoter region of
the  LRRC4  gene by using a PromoterInspector [20],
whereas a 251-bp region located from -788 to -538 was
identified as the LRRC4 promoter by using a Promoter-
Scan program [21]. We detected two CpG islands that
spanned positions -2151 to -433 and -366 to -101 using
the EMBOSS CpGplot program [22] (Figure 1). Finally, a
genomic DNA fragment that spanned positions -2475 to -
101 relative to the initiation codon ATG of the LRRC4
Analysis of the LRRC4 5' upstream regulatory region by bioinformatics Figure 1
Analysis of the LRRC4 5' upstream regulatory region by bioinformatics. The regions showing the putative promoter 
activity and CpG islands are shown as a square box, a hatched box and dotted boxes, respectively. The translation start site is 
position +1 and the rest of the sequence is numbered relative to it.
-538
 ATG
+1
-101 -366 -433 -2151
-750 -1500 -3000 -2250
-788
605bp promoter region
PromoterInspector Program
-210 -814
251bp promoter region
PromoterScan program
1719bp CpG island and 266 bp CpG island
EMBOSS CpGplot Program BMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
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gene was amplified by PCR. The PCR product was cloned
into the T/A cloning vector pGEMT-Easy (Promega) (Data
not shown).
Functional analysis of the LRRC4 promoter by 5' upstream 
deletion
To identify the promoter region of the LRRC4 gene, five
constructs of progressive deletion spanning positions -
2475 to -101 were generated (pGL3-2475/-101, pGL3 -
1483/-101, pGL3-835/-101 and pGL3-293/-101) and
cloned to upstream of the luciferase reporter gene in the
pGL3-enhancer vector (Promega). Transient transfection
experiments were carried out using Cos7 and Hela cells,
respectively. The luciferase activity driven by LRRC4 pro-
moter constructs was measured 48 h after transfection.
Expression levels were corrected for variable transfection
efficiencies by cotransfection with a plasmid directing the
β-galactosidase expression.
As shown in Figure 2, in Cos7 and Hela cells, luciferase
expression driven by the constructs pGL3-2475/-101,
pGL3-1483/-101, pGL3-835/-101 and pGL3-835/-293
exhibited similarly high levels, but the reporter driven by
construct pGL3-293/-101 showed little luciferase activity.
Thus, the sequence spanning position -835 to -293 rela-
tive to the translation start site of LRRC4 functions as a
promoter. MethPrimer program analysis shows that the
LRRC4 promoter region has high G/C content (approxi-
mately 70%) and characteristics of a CpG island [23]. In
addition, this promoter region has no TATA box or CAAT
box.
DNA methylation suppresses LRRC4 promoter activity
The presence of a CpG island suggested the possibility that
the gene might be regulated through changes in the meth-
ylation status, which have been shown to cause gene
silencing [24,25]. To analyze the effects of DNA methyla-
tion on promoter activity, LRRC4 promoter reporter con-
struct pGL3-835/-293 was treated with or without SssI
methylase to methylate the promoter in vitro. In vitro-
methylated or mock-methylated LRRC4  promoter con-
structs were transfected into Cos7 and Hela cells along
with SV40β-galactosidase vector. Firefly luciferase activity
was measured in cell lysates as shown in Figure 3A. It can
be seen that LRRC4 promoter activity was strongly sup-
pressed by methylation in both cell lines. The same result
was verified in SF126 and SF767 cell lines (Figure 3B).
Methylation of the LRRC4 promoter in glioma cell lines 
and biopsies
Our previous study showed that the expression of LRRC4
was absent in glioma cell lines SF126 and SF767 [18].
Moreover, DNA sequence analysis failed to identify any
mutation in the LRRC4 coding region, except for one Sin-
gle Nucleotide Polymorphisms site hat does not affect
amino acid sequences [18]. To clarify the mechanism of
LRRC4 inactivation in these two cell lines, methylation-
specific PCR was used to examine the methylation status
of the LRRC4 promoter. Both SF767 and SF126 cell lines
showed methylation of the LRRC4 promoter. The methyl-
ated sequence was obtained and is shown in Figure 4A.
To investigate whether aberrant methylation of the LRRC4
in glioma cell lines reflects an epigenetic event occurring
in primary glioma, we next examined 30 primary glioma
biopsies and three tissue specimens of normal brain for
LRRC4  methylation. Some methylation analyses are
shown in Figure 4B. It was demonstrated that the LRRC4
promoter was free from methylation in the three normal
brain tissue samples, but was methylated to different
extents in the 30 primary gliomas.
Bisulfite sequence analysis of promoter region of LRRC4
To determine a more detailed map of the methylation in
the LRRC4 promoter, we performed bisulfite sequencing
around the promoter region of the LRRC4 gene in some of
the glioma biopsies and cell lines studied above. In order
to cover the whole promoter region of LRRC4, two PCR
regions were amplified using primers that avoid CpG
sites. Region 1 spans -934 to -529 relative to the LRRC4
translation start site, including 48 CpG sites. Region 2 cov-
ers -550 to -197 relative to the LRRC4 translation start site,
including 21 CpG sites. Bisulfite sequencing of 10 individ-
ual clones of PCR products of both Region 1 and Region
Deletion analysis of the LRRC4 promoter Figure 2
Deletion analysis of the LRRC4 promoter. Luciferase 
activity of the deleted constructs in Cos7 and Hela cells. 
Luciferase activity in Cos7 and Hela cells is represented by 
the black histogram and gray histogram, respectively. All 
transfection experiments were repeated at least three times, 
and luciferase activity was normalized by using β-galactosi-
dase as an internal standard. Mean data ± standard errors are 
shown. In both cell lines, the construct from -835 to -293 
was sufficient to mediate maximal promoter activity.
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2 from primary glioma biopsies (T5 and T10) and cell
lines (SF126 and SF767) revealed densely methylated
CpGs within the promoter regions compared to normal
brain tissue (Figure 5). Whereas not all CpGs around the
LRRC4  promoter are methylated, most of them are in
SF126 and SF767 glioma cell lines. However, in the pri-
mary glioma tissue samples (T5 and T10), the methyla-
tion pattern appeared much more heterogeneous and
varied in density in different clones of the same sample.
This may be due to mixed cellularity in tissue samples.
5-Aza-dC induced the expression of LRRC4 in glioma cell 
lines
In order to demonstrate a functional association between
LRRC4 promoter methylation and its gene inactivation, a
DNA demethylating agent, 5-Aza-2'-deoxycytidine (5-
Aza-dC), was used to treat SF126 and SF767 cell lines. By
RT-PCR analysis, LRRC4  expression was detected after
treatment with 5-Aza-dC in both cell lines (Figure 6A).
Moreover,  LRRC4  expression increased with increasing
dosage of 5-Aza-dC. LRRC4 expression was highest when
induced by 15 μM 5-Aza-dC in SF767 cells, but in SF126
cells LRRC4 expression was highest when induced by 10
μM 5-Aza-dC.
LRRC4 promoter activity is suppressed by methylation in  vitro Figure 3
LRRC4 promoter activity is suppressed by methyla-
tion in vitro. A. Luciferase activity assays showing LRRC4 
promoter repression in response to methylation. Methylated 
(SssI) or mock-methylated LRRC4 promoter luciferase 
reporter constructs were transfected into Cos7 and Hela 
cells. Luciferase activity was measured in cell extracts 48 h 
after transfection. Luciferase activity in Cos7 and Hela cells is 
represented by the black and gray histograms, respectively. 
Luciferase activity was normalized using β-galactosidase as an 
internal standard. The results are shown as the mean ± SD of 
3 independent experiments. B.LRRC4 promoter activity sup-
pressed by methylation was verified in glioma cell lines SF126 
and SF767.
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Methylation of the LRRC4 promoter in glioma Figure 4
Methylation of the LRRC4 promoter in glioma. A. 
Methylation of the LRRC4 promoter in glioma cell lines SF126 
and SF767. DNA from the indicated glioma cell lines was 
bisulfite-modified and analyzed for methylation of the LRRC4 
promoter by methylation-specific PCR analysis. The presence 
of a PCR product in lane U indicates unmethylated LRRC4. 
The presence of a PCR product in lane M indicates the meth-
ylated LRRC4. B. Schematic presentation of methylation anal-
ysis of the LRRC4 gene promoter using MSP in tumor samples 
(T) taken from patients with glioma and three normal brain 
tissue samples (N).BMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
Page 7 of 9
(page number not for citation purposes)
To confirm that reactivation of LRRC4 mRNA expression
in glioma cell lines was caused by demethylation of the
LRRC4 promoter, methylation-specific PCR was used to
detect methylation status changes in the LRRC4 promoter
in the SF767 and SF126 cell lines after 5-Aza-dC treat-
ment. Figure 6B shows that 5-Aza-dC results in the partial
demethylation of LRRC4.
Discussion
Inactivation of tumor-suppressor genes plays an impor-
tant role in malignant brain tumor formation and pro-
gression. Genetic mechanisms such as mutation, deletion,
and structural chromosome rearrangement are known to
inactivate tumor-suppressor genes. Our previous studies
demonstrated that the expression of the LRRC4 gene was
Bisulfite sequence analysis of LRRC4 promoter Figure 5
Bisulfite sequence analysis of LRRC4 promoter. Methylation status of CpG sites around the LRRC4 promoter region 
were analyzed in glioma cell lines (SF767 and SF126), primary glioma (T5 and T10) and normal brain tissue. Region 1 spans -934 
to -529 relative to the LRRC4 translation start site, including 48 CpG sites. Region 2 spans -550 to -197 relative to the LRRC4 
translation start site, including 21 CpG sites. The arrow represents the region amplified by methylation-specific PCR. Each row 
represents an individual subclone. Open circles represent unmethylated CpGs. Filled circles represent methylated CpGs.
Region 1 Region 2 
-934 -529 -197 -550
SF767
SF126
T5
T10
Normal
brainBMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
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not only highly specific in brain tissue [26], but also a can-
didate tumor-suppressor gene that may be involved in the
pathogenesis of malignant gliomas. However, no genetic
alterations of the LRRC4 coding region were found in gli-
oma. Based on these data, we speculated that the absence
or down-regulation of LRRC4 expression in glioma may
be caused by the 5' upstream regulatory sequence.
In the present study, we cloned and characterized 2375 bp
(-2475 to -101) of the 5' genomic region of the LRRC4
gene, which shows baseline promoter activity. Further-
more, transfection experiments using a series of 5'-deleted
constructs demonstrated that the region -835 to -293 is
sufficient to mediate maximal promoter activity. This
region can also drive eGFP expression in the eGFP-
reporter plasmid (data not shown). These results suggest
that we have found a function of the LRRC4 promoter.
The functional LRRC4 promoter region is a TATA- and
CATT- less, high GC content region and has characteristics
of a CpG island. This is consistent with brain-specific gene
LRRC4  since many tissue-specific genes possess CpG
islands in regulatory regions [27].
It is well known that aberrant methylation of CpG islands
is one of the major modes of inactivation of tumor sup-
pressor genes in cancer, and a growing list of genes are
being identified as abnormal methylation of promoters
having CpG islands [28]. Here, the LRRC4 promoter was
found to be methylated in two glioma cell lines (SF126
and SF767) and all 30 primary gliomas that we have col-
lected, but not in the normal brain tissue samples, sug-
gesting that LRRC4 methylation is a tumor-specific event.
Furthermore, there was no correlation between clinical
stage, sex or age and LRRC4 methylation. Methylation of
LRRC4 was detected in both the early and late stages of gli-
oma, indicating that the inactivation of the LRRC4 gene
might be essential in the early development of glioma and
persist through the course of development.
Treatment of SF126 and SF767 cells with 5-Aza-dC
restored LRRC4 expression, which suggests that aberrant
hypermethylation of the promoter is directly responsible
for transcription inactivation of its expression in glioma
cell lines. The molecular mechanism through which DNA
methylation silences gene expression is not fully under-
stood. DNA methylation may directly interfere with the
binding of transcription factors, resulting in the transcrip-
tional repression of the associated gene [29,30]. In addi-
tion, methyl-binding domains containing proteins
(MBDs) may bind to areas of dense DNA methylation and
recruit histone deacetylases and transcriptional repressor
complexes, which is refractory to transcription [31].
Bisulfite sequence analysis of the CpG island around the
LRRC4 promoter reveals dense methylation of CpG sites
in glioma cell lines and tissues compared with non-tumor
brain specimens (Figure 5). Taken together, these findings
suggest that promoter methylation is an important mech-
anism in the inactivation of LRRC4 in glioma.
The present study implies that methylation-mediated
inactivation of LRRC4 is involved in the initiation and
development of glioma. Since LRRC4 promoter methyla-
tion is found in glioma but not in the normal brain, it may
distinguish tumors from normal tissue and serve as a
promising biomarker for diagnosis. Our previous study
indicated that LRRC4 may be an adhesive protein or/and
receptor, and it inhibited glioma invasion and metastasis
[32]. Since the ability of invasion and metastasis is closely
related to prognosis in glioma, LRRC4 methylation may
also be a biomarker for prognosis. In addition, our find-
ings demonstrate that methylase inhibitor can reverse
LRRC4 expression in glioma, and it is possible to restore
its function as tumor suppressor gene at some degree. This
shows that LRRC4 may be a potential target for therapy.
Of course, all of these hypotheses must be further studied
using a large sample analysis.
Conclusion
In summary, methylation-mediated inactivation of
LRRC4 is a frequent and glioma-specific event that may be
a potential biomarker for diagnosis and prognosis, or a
useful target for therapy.
5-Aza-dC induced the expression of LRRC4 in glioma cell  lines Figure 6
5-Aza-dC induced the expression of LRRC4 in glioma 
cell lines. A. Glioma cell lines SF767 and SF126 were treated 
with five different doses of 5-Aza-Dc (0, 2.5, 5, 10 and 15 
μM), as indicated above each lane, for four days. Total RNA 
was isolated from control, and treated cells were then ana-
lyzed by RT-PCR using the LRRC4 primer set (top panel) and 
GAPDH primer set (bottom panel). B. Glioma cell lines 
SF767 and SF126 were treated with 5 μM 5-Aza-dC for four 
days. DNA was isolated and bisulfite-modified, and then ana-
lyzed for methylation of the LRRC4 promoter by methylation-
specific PCR. The presence of a PCR product in lane U indi-
cates unmethylated LRRC4. The presence of a PCR product 
in lane M indicates the methylated LRRC4.BMC Molecular Biology 2008, 9:99 http://www.biomedcentral.com/1471-2199/9/99
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